"Antipsychotic Drug Discovery: Current State Affairs and Looking into the Future"

Baltimore, MD US
May 9, 2018

About this Lecture:

Antipsychotic medications are used first line for the treatment of psychotic disorders such as schizophrenia.  These medications are only partially effective in many cases and are associated with significant adverse outcomes.  There is a clear need for more efficacious and safer treatments but there is debate in the field about how such treatments can be developed.  This lecture will argue that deeper knowledge of underlying neurobiology of psychosis is critical for this endeavor, and will present examples of promising approaches that take advantage of known neurobiology.  I will end with discussing our work on brain bioenergetics in psychotic disorders and the potential treatment approaches indicated by this work.

 

About this Presenter:

A native of Istanbul, Turkey, Dr. Öngür obtained his M.D./Ph.D. degree from Washington University in St.Louis in 2000 and completed his psychiatric residency training at the MGH/McLean Adult Psychiatry program.  He is currently the Chief of the Psychotic Disorders Division, responsible for all clinical services serving patients with psychotic disorders including a first episode psychosis subspecialty program.  In addition to his clinical work, he receives funding from the National Institute of Mental Health for clinical and brain imaging research in patients with schizophrenia and bipolar disorder.  He is Professor of Psychiatry at Harvard Medical School and the author of more than 150 articles on research into the neurobiology of bipolar disorder and schizophrenia.  He has won awards from the Harvard Medical School for his teaching and mentoring. He is the incoming Editor in Chief of JAMA Psychiatry, a premier journal in the field. He is also a fellow of the ACNP and the APA, and a member of the NARSAD Scientific Council.

 

 

 

 

Target Audience

This activity is intended for physicians, nurses, psychologists, social workers, counselors and mental health professionals.

Learning Objectives

1. Discuss shortcomings of existing antipsychotic medications.

2. Describe a neurobiological framework for developing new treatments for psychotic disorders.

3. Describe the nature of bioenergetic brain abnormalities in schizophrenia.

Course summary
Available credit: 
  • 1.50 ACEP NBCC clock hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC Contact hours for Nurses
  • 1.50 Category I credits for Social Workers
  • 1.50 CEU Hours for Psychologists
  • 1.50 Participation
Course opens: 
05/07/2018
Course expires: 
05/31/2018
Event starts: 
05/09/2018 - 12:00pm
Event ends: 
05/09/2018 - 1:00pm
Fee:
$0.00
Sheppard Pratt Health System
6501 North Charles Street
Conference Center
Baltimore, MD 21204
United States
+1 (410) 938-4593

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers and speakers have been asked to disclose any relationship he /she or their spouse/partner has with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt Health System, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

Dost Öngür, M.D., Ph.D. reports having no financial interest, arrangement or affiliation with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months. He will discuss the effectiveness of antipsychotic medications and provide real-life challenges in the use of those medications in this presentation.

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months: Ellen Mongan, M.D., Caroline Cahn, LCSW-C, Tom Flis, LCPC, Faith Dickerson, Ph.D., Robert Roca, M.D., Drew Pate, M.D., Meena Vimalananda, M.D., Briana Riemer, M.D. Ernestine Cosby, APRN, Darby Subotich, RN, MSN, Rick Wallace, RN, MSN, Jacqueline Williams-Porter, RN, MBA, Jennifer Tornabene, and Bonnie Katz.

 

 

Physician Statement: Sheppard Pratt Health System is accredited by The Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity.  Sheppard Pratt Health System designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Statement: Sheppard Pratt Health System is an approved provider of continuing nursing education by Maryland Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity is approved for 1.5 contact hours for nurses.

Psychologist Statement: Sheppard Pratt Health System is authorized by the State Board of Examiners of Psychologists as a sponsor of continuing education. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity.  Sheppard Pratt Health System designates this educational activity for a maximum of 1.5 CEU hours for Psychologists. Psychologists should claim credit commensurate with the extent of their participation in the activity.

Social Worker Statement: Sheppard Pratt Health System is authorized by the Board of Social Work Examiners of Maryland to offer continuing education for Social Workers.  Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity is approved for 1.5 CEU contact hours in Category 1 credits for Social Workers.

Counselor Statement:  Sheppard Pratt Health System has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 5098.  Programs that do not qualify for NBCC credit are clearly identified.  Sheppard Pratt Health System is solely responsible for all aspects of the program.  This activity is available for 1.5 NBCC clock hours.

Available Credit

  • 1.50 ACEP NBCC clock hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC Contact hours for Nurses
  • 1.50 Category I credits for Social Workers
  • 1.50 CEU Hours for Psychologists
  • 1.50 Participation

Price

Fee:
$0.00
Please login or register to take this course.